NCT06540300

Brief Summary

Non-suicidal self-injury (NSSI) refers to a series of direct and consequently repeated injuries to one's body without suicidal intent. At present, it has become an important issue of mental disorders. This article focuses on the formation mechanism of NSSI and the intervention effect of rTMS on NSSI patients. At the same time, NSSI patients are collected, a treatment plan is designed to complete a two-week treatment, and the results are analyzed. The aim is to provide theoretical basis for the clinical diagnosis and treatment of NSSI, and also to provide reference for the clinical diagnosis and treatment of NSSI patients.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
8mo left

Started Jun 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Jun 2024Jun 2027

Study Start

First participant enrolled

June 30, 2024

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

July 10, 2024

Completed
27 days until next milestone

First Posted

Study publicly available on registry

August 6, 2024

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2027

Expected
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2027

Last Updated

July 24, 2026

Status Verified

July 1, 2026

Enrollment Period

2.9 years

First QC Date

July 10, 2024

Last Update Submit

July 23, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Ottawa Self-injury Inventory

    OSI was evaluated by professionally trained doctors (non experimental intervention) at baseline and two weeks after treatment to assess the effectiveness of the treatment. Comparing the differences in self harm thoughts and behaviors between the baseline period and the intervention group and the control group, p\<0.05 indicates a significant difference.

    2 weeks

  • Magnetic resonance imaging

    2 weeks

Study Arms (2)

Effects of rTMS on NSSI

EXPERIMENTAL

Exploring the effectiveness of rTMS intervention in NSSI patients using the Ottawa Self Injury Scale and other scales as research subjects

Other: rTMS stimulation of left M1

rs-fMRI-functional connectivity

EXPERIMENTAL

Based on rs fMRI technology, imaging methods were used to analyze the brain images of patients and explore the changes in functional connectivity of brain regions before and after intervention in two groups of subjects.

Other: rTMS stimulation of left M1

Interventions

This study employed low-frequency repetitive transcranial magnetic stimulation (low-frequency rTMS) targeting the left primary motor cortex (M1 area). The stimulation intensity was set at 110% of the resting motor threshold (RMT). The single-session stimulation protocol was as follows: continuous stimulation at 1 Hz for 60 seconds, followed by a 5-second interval, with this cycle repeated 20 times. Thus, the total number of pulses per session was 1,200. Two sessions were administered daily, with a 40-minute interval between sessions. Treatment was conducted for 5 consecutive days per week, with 2 rest days, for a total of 2 weeks (10 treatment days). Each patient received a total of 24,000 pulses throughout the entire course. Sham stimulation utilized identical stimulation parameters as active stimulation (including frequency, intensity, duration, and number of repetitions), but employed a sham coil. This coil was identical in appearance to the active stimulation coil, producing simila

Effects of rTMS on NSSIrs-fMRI-functional connectivity

Eligibility Criteria

Age10 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Meets the NSSI diagnostic criteria recommended in DSM-5;
  • The Chinese version of the Brief International Neuropsychiatric Interview (MINI) screen for diagnostic compliance;
  • Age :10-55 years old;
  • Right hand;
  • The paitent voluntarily participate and sign the informed consent form for this study (signed by participants under the age of 18 and their families);
  • Able to understand written language and cooperate with questionnaire surveys.

You may not qualify if:

  • History of severe substance abuse;
  • The patient has other serious mental disorders, neurological disorders, or physical illnesses; 3、Previously experienced epileptic seizures;
  • 、Pregnant or lactating women; 5、Contraindications to magnetic resonance imaging and transcranial magnetic stimulation; 6、Unable or refused to provide written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing Brain Hospital

Nanjing, Jiangsu, 210029, China

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study used a randomized, double-blind study method that controlled true and false stimuli. Except for the study leader, neither the actual operators nor the patients themselves knew whether they were receiving real or fake stimuli. A two factor mixed trial design was adopted, with a detection time of 2 (pre stimulus vs post stimulus) x 2 (stimulus type: left M1 vs pseudo stimulus). The stimulus type was an inter subject factor, and the detection time was an intra subject factor. The enrolled NSSI patients were randomly divided into a study group (left M1 group) and a control group (pseudo stimulus group) using a random number table method. Collect general demographic scales, symptom scales, and magnetic resonance imaging data before treatment, and conduct symptom scale retesting and magnetic resonance imaging data collection 2 weeks after treatment.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate chief physician

Study Record Dates

First Submitted

July 10, 2024

First Posted

August 6, 2024

Study Start

June 30, 2024

Primary Completion (Estimated)

May 30, 2027

Study Completion (Estimated)

June 15, 2027

Last Updated

July 24, 2026

Record last verified: 2026-07

Locations